Table 2. Outcomes.
| Overall (n = 153) | suPAR < 6ng/mL | suPAR ≥ 6 ng/mL | |||
|---|---|---|---|---|---|
| Control Group 2b (n = 48) | Control Group 1a (n = 49) | Anakinra group (n = 56) | |||
| p-valuec | |||||
| Supplementary oxygen, days, median (quartiles) | 10 (7, 17) | 7 (5, 11) | 14 (9, 20) | 10 (8, 15) | 0.032 |
| Length of stay, days, median (quartiles) | 11 (8, 19) | 10 (7, 14) | 15 (10, 23) | 11 (8, 18) | 0.008 |
| Need of high flow oxygen between days 1 and 14 n (%) | 42/153 (27.5) | 6/48 (12) | 20/49 (41) | 16/56 (29) | 0.19 |
| PaO2/FiO2 < 100, n (%) | 17/153 (11.1) | 1/48 (2.1) | 9/49 (18) | 7/56 (12) | 0.40 |
| PaO2/FiO2 < 150, n (%) | 40/153 (26.1) | 4/48 (8.3) | 23/49 (47) | 13/56 (23) | 0.011 |
| Admission to ICU, n (%) | 4/153 (2.6) | 0/48 (0) | 2/49 (4.1) | 2/56 (3.6) | >0.99 |
| Non-invasive ventilation, n (%) | 3/153 (2) | 0/48 (0) | 2/49 (4.1) | 1/56 (1.8) | 0.60 |
| Mechanical ventilation, n (%) | 1 (0.7) | 0/48 (0) | 0/49 (0) | 1/56 (1.8) | >0.99 |
| Allocation to strata of the WHO Clinical Progression Scale at day 14, n (%) | Odds ratio 0.25 (0.11–0.54) p<0.0001 d | ||||
| 0–3 | 87/149 (58.4) | 36/47 (77) | 17/49 (35) | 34/54 (64) | |
| 4–5 | 47/149 (3.5) | 9/47 (19) | 22/49 (45) | 16/54 (30) | |
| 6–9 | 9/149 (6) | 2/47 (4.3) | 5/49 (10) | 2/54 (3.8) | |
| 10 | 6/149 (4) | 0/47 (0) | 5/49 (10) | 2/54 (1.9) | |
| In-hospital death, n (%) | 11/153 (7.2) | 1/48 (2.1) | 6/49 (12) | 4/56 (7.1) | 0.51 |
a patients who retrospectively fulfilled the prescriptive criteria for anakinra but did not receive the drug.
b patients admitted for COVID-19 pneumonia but who presented with baseline suPAR < 6 ng/mL.
c p-values from the comparison between anakinra group and CG1.
d Ordinal regression analysis comparing anakinra group and CG1.